Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot

Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals touted data yesterday from a Phase II trial of its long-acting buprenorphine depot. The 47-patient trial found that CAM2038 blocks the effects of opioids and suppresses withdrawal symptoms in adults with opioid use disorder.

The in-patient trial included 5 3-day test sessions to evaluate the patients’ response to randomized intramuscular hydromorphone injections. After the 1st 3-day session, patients were randomized to weekly CAM2038 at 24mg or 32mg and the assigned dose was given at day 0 and day 7.

Get the full story at our sister site, Drug Delivery Business News.

The post Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot appeared first on MassDevice.

from MassDevice http://ift.tt/2szUzNT